Spain’s Ministry of Health has confirmed more than a hundred cases of a rare form of cancer associated with breast implants, with most diagnoses occurring in women fitted with textured prostheses.
According to the Spanish Agency of Medicines and Medical Devices (Aemps), a total of 111 confirmed cases of anaplastic large cell lymphoma linked to breast implants (BIA-ALCL) had been recorded by 2025. Since monitoring began in 2012, the agency has received 146 suspected reports of the condition through its medical device surveillance system.
The findings are detailed in the agency’s sixth follow-up report under the national protocol for detecting and studying this type of lymphoma. The monitoring programme has been carried out in coordination with medical associations and European regulatory bodies to better understand the disease and track its occurrence across Spain.
Regional data shows that Madrid has recorded the highest number of reported cases, followed by Andalusia, Catalonia and the Valencian Community. Health authorities have not indicated any sudden spike, but continue to review each case as part of ongoing safety assessments.
Breast implant-associated ALCL is a rare type of non-Hodgkin lymphoma that does not originate in breast tissue itself. Instead, it develops in immune system cells that may form in the scar tissue capsule surrounding an implant. Medical experts emphasise that while the condition is serious, its occurrence remains very low compared with the large number of women who have undergone breast augmentation procedures.
Aemps has reiterated that continued vigilance is essential, particularly to support early diagnosis and improve patient outcomes. The agency notes that awareness among clinicians has increased over time, contributing to more consistent reporting and investigation of suspected cases.
Researchers examining the condition believe its origins are likely to be multifactorial. Studies have explored possible links to implant texture, genetic susceptibility, chronic inflammation, and bacterial contamination around implants. However, no single cause has been definitively identified, and the exact mechanism behind the development of the lymphoma remains unclear.
Health authorities stress that current evidence does not establish a direct causal relationship between all breast implants and the disease. Instead, textured implants appear more frequently in reported cases, prompting continued scientific scrutiny and regulatory oversight.
Medical agencies across Europe continue to monitor data closely, while encouraging healthcare providers to report suspected cases promptly. The ongoing surveillance is intended to refine understanding of the condition and guide future safety recommendations for patients and surgeons alike.
